Project Grant R43EY035198
Award Date
9/1/23
Completion Date
8/31/24
Dollars Obligated
$331K
Federal Agency
National Eye Institute
Federal Grant Program
93.867
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
The National Eye Institute (NEI), under the federal Vision Research program (CFDA 93.867), awarded a $300,001 Project Grant to Kineolabs, Inc. in Billerica, MA. The objective of this 1-year grant, which runs from July 1, 2025 to June 30, 2026, is to develop a portable, low-cost line-scan swept-source optical coherence tomography (LS-SS-OCT) imaging system. This system is intended for early detection and monitoring of age-related macular degeneration (AMD), diabetic retinopathy, and other eye...
The U.S. National Eye Institute (NEI) awarded a $184,117 Project Grant (CFDA 93.867 - Vision Research) to Oakland University to determine the role of G-coupled protein receptors GPR31 and GPR39 in the pathogenesis of diabetic retinopathy. The project aims to investigate the affinities and substrate specificities of GPR31 and GPR39 for 12- and 15-HETE metabolites in retinal endothelial cells and Müller cells under normal and hyperglycemic conditions. It will also examine the effects of GPR31 or...
The National Eye Institute (NEI), under the Department of Health and Human Services, awarded a $440,806 Project Grant (CFDA 93.867 - Vision Research) to The Research Foundation for the State University of New York (RF SUNY) to study the role of the molecular chaperone p58IPK in retinal neurons under diabetic conditions. The goal is to define the in vivo function of p58IPK in regulating protein and lipid homeostasis through the integrated stress response and lipid glycosylation pathways, and to...
This Project Grant award from the National Eye Institute (NEI), under the Vision Research federal grant program (CFDA 93.867), is providing $306,462 to Ifocus Imaging LLC to develop a software platform called OCT-ART-DR. The platform will automate the diagnosis and staging of diabetic retinopathy using optical coherence tomography angiography (OCTA) imaging and artificial intelligence. The key products to be delivered under this award include: 1) Improved AI-based segmentation of OCTA image...
The National Eye Institute (NEI) awarded a $256,296 Project Grant (CFDA 93.867 - Vision Research) to The General Hospital Corporation (Massachusetts General Hospital) to develop new "Auto-Sensing, Instantaneous Adaptive Ranging Optical Coherence Tomography (OCTA)" technology. This technology aims to expand the imaging depth range of OCTA systems, enabling improved visualization of the critical peripheral retinal microvasculature. The project will leverage advances in integrated...
The National Eye Institute (NEI) awarded a $417,162 Project Grant under the Vision Research program (CFDA 93.867) to the University of Houston System to develop and apply a polarization-sensitive swept source optical coherence tomography (PS-SSOCT) system for 3D mapping of the birefringent properties of the posterior eye in a non-human primate model. The goal is to quantify changes in birefringence within the retina, optic nerve head, and lamina cribrosa in response to changes in intraocular...
This federal Project Grant award from the National Eye Institute (NEI) under the Vision Research program (CFDA 93.867) provides $881,796 to Siloam Vision, Inc. to develop two advanced, laser-based, AI-enabled retinal imaging systems. The key innovations are: A wider field-of-view camera design that can be paired with either a scanning laser ophthalmoscope (SLO) or optical coherence tomography (OCT) system, offering 2D or 3D imaging, respectively. This aims to address an unmet need in retinopathy...
The National Eye Institute (NEI) awarded a $131,281 Project Grant under the Vision Research program (CFDA 93.867) to Northwestern University to support research on the role of myeloid cell transendothelial migration in non-proliferative diabetic retinopathy. The research aims to determine whether and when blocking CCL2-driven myeloid cell infiltration can halt the progression of inflammation in the mouse retina, and whether blocking leukocyte-endothelial interactions early in the disease...
The National Eye Institute (NEI), under the U.S. Department of Health and Human Services, awarded Piximune Inc. a $306,814 Project Grant (CFDA 93.867 - Vision Research) to develop a gene-agnostic antibody-based treatment for retinitis pigmentosa (RP), a leading cause of inherited vision loss and blindness. The project aims to address the limitations of current RP therapies by developing a novel approach that augments natural mechanisms to eliminate toxic photoreceptor debris, thereby...
This Project Grant award from the National Eye Institute (CFDA 93.867 - Vision Research) aims to develop a novel, non-invasive, and sensitive measure of retinal dysfunction. The $491,466 award, effective January 1, 2025 through December 31, 2026, will support research at the University of California, San Francisco to expand a methodology using the optokinetic reflex (OKR) to detect and monitor localized cone and inner retinal function in patients with retinitis pigmentosa and diabetic...